{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T20:38:07Z","timestamp":1792269487438,"version":"4.4.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,13]]},"DOI":"10.7759\/cureus.114501","type":"journal-article","created":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T01:07:35Z","timestamp":1786669655000},"source":"Crossref","is-referenced-by-count":1,"title":["Sunitinib-Induced Hand-Foot Skin Reaction: A Case Report"],"prefix":"10.7759","author":[{"given":"Archana","family":"Patel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rujuta","family":"Sanghvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.102309","article-title":"Amoxicillin-clavulanate-induced pityriasis rosea: a pharmacovigilance case report","volume":"18","author":"Franz C","year":"2026","unstructured":"Franz C, Handa D, Joseph G, Bhatti N, Badyal DK. Amoxicillin-clavulanate-induced pityriasis rosea: a pharmacovigilance case report. Cureus. 2026, 18:e102309. 10.7759\/cureus.102309","journal-title":"Cureus"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdn389","article-title":"Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib","volume":"19","author":"Lacouture ME","year":"2008","unstructured":"Lacouture ME, Reilly LM, Gerami P, Guitart J. Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib. Ann Oncol. 2008, 19:1955-61. 10.1093\/annonc\/mdn389","journal-title":"Ann Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.4103\/ijd.IJD_481_20","article-title":"Hand-foot skin reaction with sunitinib: a rare case report with review of literature","volume":"65","author":"Das S","year":"2020","unstructured":"Das S, Roy AK, Barman S, Roy A. Hand-foot skin reaction with sunitinib: a rare case report with review of literature. Indian J Dermatol. 2020, 65:522-5. 10.4103\/ijd.IJD_481_20","journal-title":"Indian J Dermatol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.12-1-107","article-title":"Food and Drug Administration drug approval summary: sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma","volume":"12","author":"Rock EP","year":"2007","unstructured":"Rock EP, Goodman V, Jiang JX, et al.. Food and Drug Administration drug approval summary: sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma. Oncologist. 2007, 12:107-13. 10.1634\/theoncologist.12-1-107","journal-title":"Oncologist"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2007.07.022","article-title":"Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors","volume":"29","author":"Adams VR","year":"2007","unstructured":"Adams VR, Leggas M. Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors. Clin Ther. 2007, 29:1338-53. 10.1016\/j.clinthera.2007.07.022","journal-title":"Clin Ther"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1586\/14737140.2014.941815","article-title":"The use of sunitinib in renal cell carcinoma: where are we now?","volume":"14","author":"Czarnecka AM","year":"2014","unstructured":"Czarnecka AM, Szczylik C, Rini B. The use of sunitinib in renal cell carcinoma: where are we now?. Expert Rev Anticancer Ther. 2014, 14:983-99. 10.1586\/14737140.2014.941815","journal-title":"Expert Rev Anticancer Ther"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.4236\/pp.2016.78043","article-title":"Pazopanib induced hand-foot syndrome in a patient previously treated with sunitinib: a possible cumulative skin toxicity?","volume":"7","author":"Cozzani E","year":"2016","unstructured":"Cozzani E, Javor S, Ottoboni S, Parodi A. Pazopanib induced hand-foot syndrome in a patient previously treated with sunitinib: a possible cumulative skin toxicity?. Pharm Pharmacy. 2016, 7:354-8. 10.4236\/pp.2016.78043","journal-title":"Pharm Pharmacy"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group","volume":"5","author":"Oken MM","year":"1982","unstructured":"Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982, 5:649-55. 10.1097\/00000421-198212000-00014","journal-title":"Am J Clin Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.136.3.300","article-title":"Natural history of erythromelalgia: presentation and outcome in 168 patients","volume":"136","author":"Davis MD","year":"2000","unstructured":"Davis MD, O'Fallon WM, Rogers RS 3rd, Rooke TW. Natural history of erythromelalgia: presentation and outcome in 168 patients. Arch Dermatol. 2000, 136:330-6. 10.1001\/archderm.136.3.300","journal-title":"Arch Dermatol"},{"key":"ref10","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. (2017). Accessed. July 30, 2026: https:\/\/dctd.cancer.gov\/research\/ctep-trials\/for-sites\/adverse-events\/ctcae-v5-5x7.pdf."},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.6004\/jadpro.2016.7.3.18","article-title":"Management of dermatologic toxicities associated with targeted therapy","volume":"7","author":"Lacouture ME","year":"2016","unstructured":"Lacouture ME. Management of dermatologic toxicities associated with targeted therapy. J Adv Pract Oncol. 2016, 7:331-4. 10.6004\/jadpro.2016.7.3.18","journal-title":"J Adv Pract Oncol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv244","article-title":"Regorafenib-associated hand-foot skin reaction: practical advice on diagnosis, prevention, and management","volume":"26","author":"McLellan B","year":"2015","unstructured":"McLellan B, Ciardiello F, Lacouture ME, Segaert S, Van Cutsem E. Regorafenib-associated hand-foot skin reaction: practical advice on diagnosis, prevention, and management. Ann Oncol. 2015, 26:2017-26. 10.1093\/annonc\/mdv244","journal-title":"Ann Oncol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu296","article-title":"Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America","volume":"59","author":"Stevens DL","year":"2014","unstructured":"Stevens DL, Bisno AL, Chambers HF, et al.. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America. Clin Infect Dis. 2014, 59:147-59. 10.1093\/cid\/ciu296","journal-title":"Clin Infect Dis"},{"key":"ref14","unstructured":"SUTENT (sunitinib malate) capsules, for oral use. (2021). Accessed. August 10, 2026: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/021923s064lbl.pdf."},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo CA","year":"1981","unstructured":"Naranjo CA, Busto U, Sellers EM, et al.. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981, 30:239-45. 10.1038\/clpt.1981.154","journal-title":"Clin Pharmacol Ther"},{"key":"ref16","unstructured":"The use of the WHO-UMC system for standardised case causality assessment. (2013). Accessed. August 11, 2026: https:\/\/www.who.int\/docs\/default-source\/medicines\/pharmacovigilance\/whocausality-assessment.pdf."}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/515226-sunitinib-induced-hand-foot-skin-reaction-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T01:07:36Z","timestamp":1786669656000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/515226-sunitinib-induced-hand-foot-skin-reaction-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,13]]},"references-count":16,"URL":"https:\/\/doi.org\/10.7759\/cureus.114501","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,13]]}}}